Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sabrina Falkowski1

  • 1Service oncologie, polyclinique de Limoges, site Chénieux, 18, rue du Général-Catroux, 87000 Limoges, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary

Resistance to tyrosine kinase inhibitors (TKIs) in kidney cancer affects about 25% of patients. Understanding intrinsic and acquired resistance mechanisms is crucial for developing new therapeutic strategies to improve outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.

European journal of cancer (Oxford, England : 1990)·2022
Same author

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

Cancers·2021
Same author

Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients.

The pharmacogenomics journal·2020
Same author

Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives.

Therapeutic drug monitoring·2019
Same author

Vaginal metastasis of renal clear-cell cancer.

The Gulf journal of oncology·2018
Same author

Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.

BMC cancer·2017

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies, specifically tyrosine kinase inhibitors (TKIs), have improved outcomes for metastatic kidney cancer.
  • However, a significant subset of patients (approx. 25%) shows no benefit, and acquired resistance develops in many others within 6-12 months.

Purpose of the Study:

  • To summarize and analyze the mechanisms of resistance to TKIs in renal cancer.
  • To identify resistance processes and propose rational therapeutic approaches for improved clinical benefit.

Main Methods:

  • Literature review and synthesis of current research on TKI resistance in renal cancer.
  • Analysis of proposed models of tumor resistance: intrinsic (pre-existing) and adaptive (acquired).

Main Results:

Keywords:
Acquired and intrinsicCancer du reinDrug resistanceInhibiteurs de tyrosineMetastatic renal cellRésistance acquiseRésistance intrinsèqueTyrosine kinaseadaptativecarcinomainhibitorskinasemétastatiqueresistance

Related Experiment Videos

  • Intrinsic resistance is linked to redundant pro-angiogenic pathways.
  • Acquired resistance involves activation of alternative pathways or upregulation of the VEGF pathway.
  • Two models of resistance (intrinsic and adaptive) are described, impacting treatment efficacy.

Conclusions:

  • Understanding TKI resistance mechanisms is essential for overcoming therapeutic limitations in kidney cancer.
  • Developing novel treatment strategies, including combinations and sequences of TKIs and immunotherapy, is critical for improving patient outcomes.